The EU pharmaceutical reform will reshape market exclusivity for orphan medicinal products. Under the Council's September 2026 position, standard orphan medicines would receive nine years of exclusivity, breakthrough orphan medicinal products eleven years, and orphan medicines authorised on the basis of well-established medicinal use four years. Extensions for additional orphan indications could bring the total to thirteen years in certain cases.
The proposed rules change the regulatory incentives for developing treatments for rare diseases. The accompanying directive also introduces an incentive linked to clinical trials using evidence-based comparators, potentially generating evidence relevant to subsequent health technology assessment (HTA). The criteria for regulatory protection and those applied in the EU joint clinical assessment (JCA) nevertheless remain distinct.
The EU pharmaceutical reform introduces three categories of orphan market exclusivity
The current ten-year orphan market exclusivity period would be replaced by a differentiated framework. The proposed regulation distinguishes standard orphan medicinal products, breakthrough orphan medicinal products and products authorised on the basis of well-established medicinal use.
Article 73 of Council document ST 7105/26 provides for the following periods:
|
Category |
Market exclusivity |
|---|---|
|
Standard orphan medicinal products |
9 years |
|
Breakthrough orphan medicinal products |
11 years |
|
Orphan medicinal products based on well-established medicinal use |
4 years |
Orphan market exclusivity does not protect an active substance as such. In principle, it prevents the authorisation of a similar medicinal product for the same therapeutic indication, or the extension of an existing authorisation to that indication, during the protected period.
Exceptions remain possible. A similar product may, for example, be authorised if the original marketing authorisation holder consents, cannot supply sufficient quantities or the new product demonstrates clinical superiority. Certain applications may also be assessed before exclusivity expires without allowing the competing product to enter the market prematurely.
The differentiated periods alter the incentive structure. Standard orphan products would receive a shorter initial period, while products meeting additional clinical criteria would qualify for longer protection.
The four-year period for well-established-use products reflects a different development and authorisation pathway. It applies where authorisation relies on bibliographic evidence of an established medicinal use.
Legal basis: Article 73, ST 7105/26.
Breakthrough orphan medicinal products qualify for eleven years of market exclusivity
The eleven-year period depends on clinical criteria that go beyond ordinary orphan designation. Article 72 of the proposed regulation establishes the breakthrough orphan medicinal product category.
The product must first meet the general requirements applicable to orphan medicinal products. In addition, Article 72 requires that no medicinal product be authorised in the EU for the orphan condition concerned and that use of the new product result in a clinically relevant reduction in disease morbidity or mortality in the relevant patient population.
This is narrower than ordinary orphan designation. Under certain circumstances, a product can obtain orphan designation despite the existence of a satisfactory treatment method, provided it offers a significant benefit.
Significant benefit alone is not sufficient for breakthrough classification. The proposed regulation specifically requires the absence of an authorised medicinal product for the condition and a clinically relevant reduction in morbidity or mortality.
This distinction matters for clinical development. Endpoint selection and the strength of the clinical findings may determine whether a product qualifies for the longer period.
Regulatory breakthrough classification should not, however, be equated with a finding of added benefit in a national HTA procedure. The assessments address different questions and may reach different conclusions using evidence from the same clinical studies.
Legal basis: Articles 65 and 72, ST 7105/26.
Additional orphan indications may extend exclusivity to thirteen years
The reform provides an extension when an orphan medicine is authorised for additional rare conditions. Under Article 74, the exclusivity period may be extended by twelve months where the marketing authorisation holder obtains an additional therapeutic indication for a different orphan condition within the prescribed timeframe.
The new indication must be authorised at least two years before the existing exclusivity period expires. Up to two extensions are possible, provided they concern different orphan conditions.
The resulting maximum periods differ by category:
|
Initial category |
Initial exclusivity |
With two extensions |
|---|---|---|
|
Standard orphan medicinal product |
9 years |
11 years |
|
Breakthrough orphan medicinal product |
11 years |
13 years |
|
Well-established-use orphan medicinal product |
4 years |
No extension under Article 74 |
The extension mechanism therefore does not apply to all three categories. Orphan products authorised on the basis of well-established medicinal use are excluded from Article 74.
Article 73 also prevents multiple orphan authorisations for the same active substance from automatically generating separate full exclusivity periods. In principle, the period starts with the first orphan marketing authorisation in the EU.
For programmes involving several potential orphan indications, the timing of indication development therefore matters. The relevant considerations include when additional authorisations are granted and whether the statutory conditions for extension are satisfied.
The mechanism encourages development in further orphan conditions without granting a fresh full exclusivity period for each new authorisation.
Legal basis: Article 73(3) and Article 74, ST 7105/26.
Orphan market exclusivity and regulatory data protection remain separate mechanisms
Orphan-specific market exclusivity exists alongside general regulatory data and market protection. These mechanisms serve different purposes and have different eligibility requirements.
Article 83 of the proposed directive ST 7106/26 provides, in principle, for eight years of regulatory data protection. During that period, other applicants cannot rely on the protected data of the reference medicinal product without the relevant entitlement.
A further year of regulatory market protection generally follows. Article 84 provides for possible extensions subject to specified conditions.
Orphan market exclusivity under Article 73 of the regulation, by contrast, restricts the authorisation of similar products for the same therapeutic indication. It does not depend solely on reliance on protected regulatory data.
Both mechanisms can be relevant to an orphan medicine, but their durations and legal conditions must be assessed separately. Not every potentially available extension can be added together.
One specific limitation concerns additional indications. Under Article 74(2) of the proposed regulation, orphan products receiving an extension of their orphan market exclusivity for new orphan indications cannot also benefit from the additional general market protection period under Article 84(2) of the directive.
This matters when assessing multi-indication development programmes. Whether a new authorisation extends protection depends on the mechanism invoked and the applicable exclusions, as well as on the clinical characteristics of the new indication.
Legal basis: Articles 73–74, ST 7105/26; Articles 83–84, ST 7106/26.
The EU pharmaceutical reform introduces an incentive for comparative clinical evidence
The proposed directive expressly links certain additional market protection incentives to clinical trials using evidence-based comparators. This connects a regulatory incentive to a feature of study design that also matters for subsequent comparative clinical assessment.
Article 84(1) provides, under specified conditions, for a twelve-month extension of regulatory market protection. For medicines containing a new active substance, this may apply where pivotal clinical trials use a relevant evidence-based comparator in line with scientific advice from the European Medicines Agency (EMA).
Use of such a comparator is not sufficient on its own. Depending on the applicable route, further conditions may concern the conduct of clinical trials in several Member States or the timing of the EU marketing authorisation application. The directive also provides a separate route where a corresponding comparative trial is not possible or appropriate.
This incentive is not specific to orphan medicinal products. It forms part of the general regulatory market protection framework and must be distinguished from orphan market exclusivity.
Recital 67 explains its relevance to evidence generation: the use of evidence-based comparators is intended to encourage clinical evidence that can also support subsequent HTA and national pricing and reimbursement decisions.
Comparator selection can therefore have a regulatory incentive dimension in addition to its methodological role in clinical development and benefit assessment.
However, acceptance of a comparator by the EMA does not automatically satisfy all requirements of a JCA. A JCA assesses relative clinical effectiveness and safety against its own assessment scope, which may cover multiple populations, interventions, comparators and outcomes.
This creates a specific consideration for clinical trial planning. A study design may be appropriate for regulatory purposes while additional analyses or evidence are needed for EU or national HTA.
Early alignment of evidence planning can also take place within Joint Scientific Consultations (JSC), where developers can obtain scientific advice on the evidence requirements for a later JCA.
Legal basis: Article 84(1) and (4), and recitals 67–68, ST 7106/26.
EU HTA and national benefit assessments retain their own evidence requirements
The new regulatory incentives do not directly change the assessment standards applied in the EU JCA or national HTA procedures. Marketing authorisation and comparative clinical assessment remain separate processes.
Recital 151 of the proposed regulation explicitly distinguishes them. Regulatory authorisation assesses quality, safety and efficacy. Comparative assessment examines the relative therapeutic value of a medicine against existing treatment options.
For orphan medicines, this distinction is particularly important. A product may meet the regulatory criteria for breakthrough classification without demonstrating all the relative effects required by the JCA.
The clinically relevant reduction in morbidity or mortality under Article 72 addresses a specific regulatory question. The JCA instead examines the comparative clinical findings available for the defined PICO questions and the reliability of that evidence.
The populations in pivotal studies may differ from those in the JCA assessment scope. Comparator selection, available outcomes and the methodological suitability of indirect comparisons may also create additional evidence requirements.
The EU Joint Clinical Assessment (JCA) process assesses relative clinical effectiveness and safety against its own assessment scope and provides a common European framework for clinical assessment. It does not replace national pricing and reimbursement decisions.
In Germany, the early AMNOG benefit assessment continues to apply. EU orphan market exclusivity neither determines the extent of added benefit nor replaces the specific statutory provisions for orphan medicines. Those provisions are themselves under debate: the current discussion on Germany's AMNOG orphan drug privilege concerns in particular the statutory presumption of added benefit and the requirements for comparative evidence.
In France, the Haute Autorité de santé (HAS) continues to assess medicines under national criteria, notably service médical rendu (SMR) and amélioration du service médical rendu (ASMR). Regulatory orphan or breakthrough classification does not automatically lead to a favourable ASMR rating.
Regulatory incentives and HTA requirements should therefore be considered together early in evidence planning, while keeping their criteria distinct.
Selection of study populations, comparators and endpoints needs to account for evidence required for authorisation and potential protection periods, as well as additional clinical questions arising in the JCA and national HTA procedures.
The EU pharmaceutical reform introduces incentives for certain forms of clinical innovation and comparative evidence generation. Whether that evidence also meets EU and national HTA requirements remains a separate methodological question.
---
Legislative status: 27 October 2026. This article analyses the Council's first-reading positions on the EU pharmaceutical reform. The proposed changes should not yet be treated as applicable law. Transitional provisions are particularly relevant to marketing authorisation applications submitted before the new regulation's date of application. Article 185(10) of the Council text retains the previous orphan exclusivity rules for such applications.